TY - JOUR
T1 - Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms
AU - Brouwer, Philip J. M.
AU - Sanders, Rogier W.
PY - 2019
Y1 - 2019
N2 - PURPOSE OF REVIEW: We will discuss recent advances in the development of nanoparticle vaccines presenting HIV-1 envelope trimer vaccines and the immunological mechanisms by which they act. RECENT FINDINGS: The multivalent presentation of Env trimers on nanoparticles is a promising strategy to increase Env immunogenicity. Recent studies have shed light on how Env nanoparticles increase lymph node trafficking and germinal center formation by using the lectin-mediated complement pathway and enhancing the interaction with naïve B cells. Meanwhile, research on different nanoparticle platforms has resulted in improved designs, such as liposomes with improved stability, and the emergence of novel platforms such as protein nanoparticles that self-assemble in vitro. Immmunogenicity studies with these nanoparticles delineate the advantages and expose the limitations of the different nanoparticle platforms. SUMMARY: It is becoming increasingly clear that HIV-1 vaccine research might benefit greatly from using nanoparticles presenting Env trimers, particularly during the priming stage of immunization. Among the different nanoparticles that are being pursued, in vitro-assembling nanoparticles allow for greater control of Env quality making them a promising nanoparticle platform.
AB - PURPOSE OF REVIEW: We will discuss recent advances in the development of nanoparticle vaccines presenting HIV-1 envelope trimer vaccines and the immunological mechanisms by which they act. RECENT FINDINGS: The multivalent presentation of Env trimers on nanoparticles is a promising strategy to increase Env immunogenicity. Recent studies have shed light on how Env nanoparticles increase lymph node trafficking and germinal center formation by using the lectin-mediated complement pathway and enhancing the interaction with naïve B cells. Meanwhile, research on different nanoparticle platforms has resulted in improved designs, such as liposomes with improved stability, and the emergence of novel platforms such as protein nanoparticles that self-assemble in vitro. Immmunogenicity studies with these nanoparticles delineate the advantages and expose the limitations of the different nanoparticle platforms. SUMMARY: It is becoming increasingly clear that HIV-1 vaccine research might benefit greatly from using nanoparticles presenting Env trimers, particularly during the priming stage of immunization. Among the different nanoparticles that are being pursued, in vitro-assembling nanoparticles allow for greater control of Env quality making them a promising nanoparticle platform.
KW - HIV-1 Env trimer
KW - liposome
KW - nanoparticle presentation
KW - self-assembling protein nanoparticle
KW - virus-like particle
UR - http://www.scopus.com/inward/record.url?scp=85067270723&partnerID=8YFLogxK
U2 - https://doi.org/10.1097/COH.0000000000000549
DO - https://doi.org/10.1097/COH.0000000000000549
M3 - Review article
C2 - 30994503
SN - 1746-630X
VL - 14
SP - 302
EP - 308
JO - Current opinion in HIV and AIDS
JF - Current opinion in HIV and AIDS
IS - 4
ER -